SkinHealth Systems Inc. (SKIN) stock
SKINNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30316% above fair value
$13.88−1.18 (-7.81%)
Close on Nov 17, 2026Market cap $1.81BP/E –Yield –
SkinHealth Systems r&d expenses
Research and development expenses are spending on new products and technology.
SkinHealth Systems's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.89M, up 28.6% year over year. For fiscal 2025 it was $5.63M, down 10.6% from the year before. The highest annual figure on record is $10.10M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.63M | -10.6% |
| FY2024 | Dec 31, 2024 | $6.30M | -37.7% |
| FY2023 | Dec 31, 2023 | $10.10M | +19.6% |
| FY2022 | Dec 31, 2022 | $8.44M | +3.0% |
| FY2021 | Dec 31, 2021 | $8.20M | +140.4% |
| FY2020 | Dec 31, 2020 | $3.41M | -26.1% |
| FY2019 | Dec 31, 2019 | $4.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.41M | +12.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.10M | +10.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.68M | +37.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.70M | +53.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.25M | +7.9% |
| Q1 FY2025 | Mar 31, 2025 | $998.00K | -64.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.22M | -59.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.11M | -39.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.16M | -59.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.81M | +20.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.05M | +110.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.84M | -15.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.88M | +10.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.34M | +4.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.45M | -22.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.17M | +15.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.60M | -13.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.23M | +53.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.88M | +118.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.88M | +225.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.99M | +400.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.45M | – |
| Q4 FY2020 | Dec 31, 2020 | $860.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $577.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $597.00K | – |
See a number that looks wrong?